UNSPSC 51343115: Zalcitabine

This classification denotes a pyrimidine antagonist with the molecular formula C9H13N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6L3XT8CB3I, chemically known as dideoxycytidine but generally known as zalcitabine, which bears US NIH Compound Identifier 24066. European Medicines Agency schedules Zalcitabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00130MIG.

UNSPSC 51343115 Zalcitabine is a Commodity code that does not reflect the pharmaceutical products and services state and local governments are actually procuring under this taxonomy assignment. Recent opportunities tagged to this code show state and local agencies sourcing antibiotic pharmaceuticals (doxycycline, ciprofloxacin) and naloxone through emergency preparedness and public health programs, not the antiviral medication named in the code itself. The issuing bodies include state departments of public health and county health authorities leveraging cooperative purchasing vehicles and standard competitive bidding processes to supply medication inventories for community health and emergency response initiatives.

Activity under this code appears in Illinois and Florida. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026 for doxycycline and ciprofloxacin totaling $2,999,999.11 across a 12-month initial term with two optional renewal years; the contract was awarded through an Invitation for Bid process (Solicitation 26482DPHPREPDB53392). Seminole County, Florida issued an IFB (IFB60459723LAS) posted June 30, 2026 with response deadline July 26, 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building. The mismatch between the code name and actual procurement scope suggests the code assignment may not align with current state and local buying patterns in this pharmaceutical category.